Overview

Efficacy and Safety Study of Gabapentin as add-on to Morphine in Paediatric Patients Affected by Chronic Pain

Status:
Withdrawn
Trial end date:
2019-10-21
Target enrollment:
Participant gender:
Summary
The objective of the study is to evaluate the efficacy of gabapentin as adjunctive therapy to morphine in the treatment of severe chronic neuropathic or mixed pain in children from 3 months to less than 18 years of age assessed by the difference in average pain scores between treatment arms at the end of the treatment period.
Phase:
Phase 2
Details
Lead Sponsor:
Pharmaceutical Research Management srl
Collaborator:
European Commission
Treatments:
Gabapentin
gamma-Aminobutyric Acid
Morphine